Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Onconova Therapeutic (ONTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 19,455
  • Shares Outstanding, K 9,490
  • Annual Sales, $ 5,550 K
  • Annual Income, $ -19,670 K
  • 36-Month Beta 0.09
  • Price/Sales 3.47
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.78 +17.12%
on 05/31/17
2.23 -6.52%
on 06/05/17
+0.04 (+2.19%)
since 05/22/17
3-Month
1.78 +17.12%
on 05/31/17
3.88 -46.27%
on 04/04/17
-0.74 (-26.07%)
since 03/22/17
52-Week
1.78 +17.12%
on 05/31/17
6.42 -67.53%
on 06/23/16
-4.08 (-66.16%)
since 06/22/16

Most Recent Stories

More News
Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes...

ONTX : 2.08 (+1.46%)
Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes,...

ONTX : 2.08 (+1.46%)
Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes,...

ONTX : 2.08 (+1.46%)
Onconova Therapeutics Announces Closing of Public Offering of Common Stock

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic...

ONTX : 2.08 (+1.46%)
Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Ramesh Kumar,...

ONTX : 2.08 (+1.46%)
Onconova Therapeutics Announces Pricing of Public Offering of Common Stock

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic...

ONTX : 2.08 (+1.46%)
Onconova Therapeutics Announces Proposed Public Offering of Common Stock

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic...

ONTX : 2.08 (+1.46%)
Company News for April 05, 2017

Company News for April 05, 2017

RDHL : 9.18 (+0.44%)
AYI : 178.44 (+2.11%)
LVNTA : 51.97 (+0.35%)
ONTX : 2.08 (+1.46%)
GNCMA : 36.25 (+0.30%)
Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval

NEW YORK, NY / ACCESSWIRE / April 5, 2017 / Onconova scored a 2-for-1 with its FDA candidate drug trials and Pluristem is on the cusp of their drug potentially having a broad military and national application....

ONTX : 2.08 (+1.46%)
PSTI : 1.37 (-0.72%)
Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting

-- Comparative biological studies with Palbociclib

ONTX : 2.08 (+1.46%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More

Business Summary

Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV,...

See More

Support & Resistance

2nd Resistance Point 2.13
1st Resistance Point 2.09
Last Price 2.08
1st Support Level 2.03
2nd Support Level 2.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.